New fundamental research could help combat treatment-resistant leukemia and prevent relapses in children and adolescents. A ...

Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Learn more about the causes, risk factors, symptoms, diagnosis, treatment types, and prognosis for acute lymphoblastic leukemia.

Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...

4. Dombret H, Gabert J, Boiron J-M, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia — results of the prospective multicenter LALA-94 trial.

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL ...

More information: Caner Saygin et al, Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis, Blood Cancer Discovery (2023).

The Food and Drug Administration (FDA) has approved Besponsa (inotuzumab ozogamicin) for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL ...